ArticleACS omega2023
Nanoarchitectonics of the Effects of Curcumin Carbon Dot-Decorated Chitosan Nanoparticles on Proliferation and Apoptosis-Related Gene Expressions in HepG2 Hepatocellular Carcinoma Cells.
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bioactive Chitosan-Alginate Films with Oregano or Turmeric: Effects on Blueberry Shelf Life and In Vitro Genotoxicity Profile.Molecules (Basel, Switzerland) · 2026Article
- Article
- Multifaceted Applications of Zerumbone-Loaded Metal-Organic Framework-5: Anticancer, Antibacterial, Antifungal, DNA-Binding, and Free Radical Scavenging Potentials.Molecules (Basel, Switzerland) · 2025Article
- Alginate and chitosan-coated ferulic acid-loaded selenium nanoparticles: synthesis, characterization, and anticancer activity against MDA-MB-231 breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Improving Drug Solubility with Polymer-Drug Conjugation: Recent Insights.Mini reviews in medicinal chemistry · 2025Review
- Cytotoxic effects of bee venom-loaded ZIF-8 nanoparticles on thyroid cancer cells: a promising strategy for targeted therapy.Medical oncology (Northwood, London, England) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines the potential anticancer properties of curcumin carbon nanodot-decorated chitosan nanoparticles (CCM@CD/CS-NP) in HepG2 hepatocellular carcinoma cells. CCM@CD/CS-NPs were synthesized, and their size, morphology, and elemental analysis were characterized. The combination of curcumin carbon dots and chitosan in the form of a nanoparticle has a number of benefits, including improved solubility and bioavailability of curcumin, enhanced stability and biocompatibility of carbon dots, and sustained release of the drug due to the mucoadhesive properties of chitosan. The purpose of this research was to examine the efficacy of curcumin carbon dot-decorated chitosan nanoparticles as an anticancer agent in the treatment of HepG2 cell lines. The cell proliferation and apoptosis-related gene expressions in HepG2 cells were assessed to investigate the potential use of nanoparticles in vitro. The IC50 value for the inhibitory effect of CCM@CD/CS-NPs on cell growth and proliferation was determined to be 323.61 μg/mL at 24 h and 267.73 μg/mL at 48 h. Increased caspase-3 and -9 activation shows that CCM@CD/CS-NPs promoted apoptosis in HepG2 cells. It was also shown that the overexpression of Bax and the downregulation of Bcl-2 were responsible for the apoptotic impact of CCM@CD/CS-NPs. The nanoparticles have been shown to have minimal toxicity to normal liver cells, indicating their potential as a safe and effective treatment for HepG2. These novel nanomaterials effectively suppressed tumor development and boosted the rate of apoptotic cell death.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.